Bacillus coagulans MTCC 5856 (LactoSpore)

Bacillus coagulans MTCC 5856 is a spore-forming probiotic strain that produces lactic acid and antimicrobial compounds to improve digestive health. This heat-stable strain survives stomach acid to colonize the intestines and modulate immune function through gut-associated lymphoid tissue.

Origin & History

Bacillus coagulans MTCC 5856, known as LactoSpore, is a spore-forming probiotic strain. It is produced through fermentation and is known for its stability and efficacy in dietary supplements.

Historical & Cultural Context

Spore-forming probiotics like Bacillus coagulans have been used in traditional medicine systems, particularly in Asia, for their robust health benefits.

Health Benefits

- Enhances digestive health by reducing bloating and gas, leading to a more comfortable digestive experience. - Boosts immune function by increasing the production of protective antibodies, enhancing the body's defense mechanisms. - Supports joint health by reducing inflammation, which can alleviate symptoms of arthritis. - Promotes skin health by reducing acne and other skin conditions through its anti-inflammatory properties. - Aids in mental well-being by reducing stress levels, leading to improved mood and cognitive function. - Improves lactose digestion by producing lactase, making it easier for lactose-intolerant individuals to enjoy dairy products. - Enhances nutrient absorption by strengthening the gut barrier, ensuring efficient uptake of essential nutrients.

How It Works

Bacillus coagulans MTCC 5856 produces lactic acid and bacteriocins that create an acidic environment inhibiting pathogenic bacteria growth. The strain activates toll-like receptors in intestinal epithelial cells, triggering NF-κB pathways that enhance immunoglobulin A production and reduce pro-inflammatory cytokines like TNF-α and IL-6. Its spore form allows survival through gastric acid, germinating in the alkaline small intestine to establish beneficial colonization.

Scientific Research

Studies, including randomized controlled trials, have shown its effectiveness in improving digestive health and reducing IBS symptoms. It is valued for its resilience and ability to survive stomach acid.

Clinical Summary

Multiple randomized controlled trials with 50-150 participants demonstrate significant reductions in abdominal pain and bloating scores within 2-4 weeks of supplementation. Studies show 30-40% improvements in digestive comfort scores and 25% increases in beneficial Lactobacillus populations in stool samples. Clinical evidence supports immune benefits through increased salivary IgA levels and reduced upper respiratory infections. However, most studies are relatively small and short-term, requiring larger long-term trials for definitive efficacy confirmation.

Nutritional Profile

Bacillus coagulans MTCC 5856 (LactoSpore) is a spore-forming probiotic bacterium and does not contribute meaningful macronutrients or micronutrients in the quantities typically used in supplementation (1–2 billion CFU per serving, approximately 15–30 mg of cell mass). Key bioactive components include: (1) Lactic acid produced via homofermentative metabolism — L(+)-lactic acid is the primary metabolic output, contributing to gut acidification and pathogen inhibition; (2) Spore coat proteins — dipicolinic acid (DPA) complexed with calcium forms the heat-stable spore core, comprising approximately 5–15% of dry spore weight, contributing to its exceptional stability at temperatures up to 90°C; (3) Bacteriocin-like inhibitory substances (BLIS) — antimicrobial peptides produced during germination that inhibit competing pathogens; (4) Short-chain fatty acids (SCFAs) — acetate and lactate are produced post-germination in the colon, supporting colonocyte energy metabolism; (5) Exopolysaccharides (EPS) — immunomodulatory surface carbohydrates that interact with gut-associated lymphoid tissue (GALT); (6) Enzymes including amylase, protease, and lipase secreted during active growth, supporting macronutrient digestion. Bioavailability note: The spore form ensures approximately 80–85% survivability through gastric acid and bile salts (pH 2–3 tolerance confirmed), with germination and metabolic activity initiating in the small intestine. Viable cell recovery in the colon is significantly higher than non-spore-forming probiotics. No caloric, vitamin, or mineral contribution is considered clinically significant at standard supplemental doses.

Preparation & Dosage

Typical dosages range from 1 to 10 billion CFUs per day. Consult a healthcare provider before use.

Synergy & Pairings

Prebiotics, Lactobacillus plantarum, Bifidobacterium breve, Aloe vera

Safety & Interactions

Bacillus coagulans MTCC 5856 is generally well-tolerated with rare mild gastrointestinal side effects like temporary gas or bloating during initial use. No significant drug interactions have been reported, though it may theoretically reduce antibiotic effectiveness when taken simultaneously. Individuals with severe immunocompromised conditions should consult healthcare providers before use. Safety during pregnancy and breastfeeding has not been established through clinical trials, so use should be avoided without medical supervision.